[go: up one dir, main page]

WO2003013420A3 - Derives d'isoprenyl et leur utilisation pour traiter et prevenir l'osteoporose et la calcification cardio-vasculaire - Google Patents

Derives d'isoprenyl et leur utilisation pour traiter et prevenir l'osteoporose et la calcification cardio-vasculaire Download PDF

Info

Publication number
WO2003013420A3
WO2003013420A3 PCT/EP2002/008917 EP0208917W WO03013420A3 WO 2003013420 A3 WO2003013420 A3 WO 2003013420A3 EP 0208917 W EP0208917 W EP 0208917W WO 03013420 A3 WO03013420 A3 WO 03013420A3
Authority
WO
WIPO (PCT)
Prior art keywords
group
prevention
treatment
osteoporosis
women
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2002/008917
Other languages
English (en)
Other versions
WO2003013420A2 (fr
Inventor
Ceer Vermeer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
VITAK BV
Original Assignee
VITAK BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by VITAK BV filed Critical VITAK BV
Priority to AU2002333378A priority Critical patent/AU2002333378A1/en
Priority to EP02794586A priority patent/EP1414387A2/fr
Publication of WO2003013420A2 publication Critical patent/WO2003013420A2/fr
Publication of WO2003013420A3 publication Critical patent/WO2003013420A3/fr
Priority to US10/770,991 priority patent/US20050176778A1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/02—Quinones with monocyclic quinoid structure
    • C07C50/06—Quinones with monocyclic quinoid structure with unsaturation outside the quinoid structure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/10—Quinones the quinoid structure being part of a condensed ring system containing two rings
    • C07C50/14—Quinones the quinoid structure being part of a condensed ring system containing two rings with unsaturation outside the ring system, e.g. vitamin K1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/007—Esters of unsaturated alcohols having the esterified hydroxy group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/612—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety
    • C07C69/616—Esters of carboxylic acids having a carboxyl group bound to an acyclic carbon atom and having a six-membered aromatic ring in the acid moiety polycyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/67—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids
    • C07C69/675—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of saturated acids of saturated hydroxy-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
    • C07C69/78—Benzoic acid esters

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

L'invention concerne un composé non toxique biologiquement actif représenté par la formule (I) ou un dérivé de celui-ci pharmaceutiquement acceptable. Dans cette formule, n est un nombre entier compris entre 1 et 14 et, de préférence, entre 2 et 4; R représente une fraction organique, de préférence, un groupe différent de 2-methyl naphthoquinone mais de structure sensiblement similaire, ou un groupe P-C(R1)-P, où chaque P représente un groupe -PO(OH)2; et R1 représente un groupe (poly)isoprényl, hydroxy, halogène (de préférence, chloro ou bromo) ou hydrogène. On utilise ces composés pour traiter ou prévenir certains troubles des mammifères, notamment des humains, par exemple, en cas de perte osseuse postménopausale chez la femme, d'ostéoporose juvénile ou sénile chez les hommes et les femmes, de calcification cardio-vasculaire et d'autres calcifications ectopiques.
PCT/EP2002/008917 2001-08-03 2002-08-05 Derives d'isoprenyl et leur utilisation pour traiter et prevenir l'osteoporose et la calcification cardio-vasculaire Ceased WO2003013420A2 (fr)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2002333378A AU2002333378A1 (en) 2001-08-03 2002-08-05 Isoprenyl derivatives and their use in the treatment and prevention of osteoporosis and cardiovascular calcification
EP02794586A EP1414387A2 (fr) 2001-08-03 2002-08-05 Derives d'isoprenyl et leur utilisation pour traiter et prevenir l'osteoporose et la calcification cardio-vasculaire
US10/770,991 US20050176778A1 (en) 2001-08-03 2004-02-02 Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01202955 2001-08-03
EP01202955.9 2001-08-03

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US10/770,991 Continuation US20050176778A1 (en) 2001-08-03 2004-02-02 Isoprenyl derivatives and their use in the title treatment and prevention of osteoporosis and cardiovascular calcification

Publications (2)

Publication Number Publication Date
WO2003013420A2 WO2003013420A2 (fr) 2003-02-20
WO2003013420A3 true WO2003013420A3 (fr) 2003-11-06

Family

ID=8180752

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2002/008917 Ceased WO2003013420A2 (fr) 2001-08-03 2002-08-05 Derives d'isoprenyl et leur utilisation pour traiter et prevenir l'osteoporose et la calcification cardio-vasculaire

Country Status (3)

Country Link
EP (1) EP1414387A2 (fr)
AU (1) AU2002333378A1 (fr)
WO (1) WO2003013420A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE361001T1 (de) 2000-05-12 2007-05-15 Vitak Bv Nahrungsmittel enthaltend vitamin k2
GB0220182D0 (en) 2002-08-30 2002-10-09 Cardiovascular Res Inst Maastr Organic compounds
US20050158329A1 (en) 2004-01-21 2005-07-21 Ghosh Swapan K. Novel phytol derived immunoadjuvants and their use in vaccine formulations
DE602006020658D1 (de) † 2005-06-03 2011-04-28 Nattopharma Asa Verwendung von Vitamin K, um die Verkalkung der Blutgefässe rückgängig zu machen
GB2476644B (en) 2009-12-23 2012-11-14 Haomamedica Ltd 1,4-Dihydro-1,4-dioxonaphtalene derivatives for the treatment of osteoporosis
EP2651250A1 (fr) * 2010-12-17 2013-10-23 VitaK B.V. Utilisation de la vitamine k pour maintenir le poids et contrôler le poids

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243849A2 (fr) * 1986-04-23 1987-11-04 Yeda Research And Development Company Limited Procédé pour la fabrication de composés du type polyprénoide
EP0636598A1 (fr) * 1993-07-26 1995-02-01 Eisai Chemical Co., Ltd. Procédé pour la préparation des dérivés de naphthoquinone et des produits intermédiaires pour leur préparation
WO1999000135A1 (fr) * 1997-06-28 1999-01-07 The Boots Company Plc Compositions de prevention et de traitement de l'osteoporose, comprenant de la vitamine k et de la vitamine d
EP1153548A1 (fr) * 2000-05-12 2001-11-14 Unilever N.V. Produit alimentaire contenant de la vitamine k2

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0243849A2 (fr) * 1986-04-23 1987-11-04 Yeda Research And Development Company Limited Procédé pour la fabrication de composés du type polyprénoide
EP0636598A1 (fr) * 1993-07-26 1995-02-01 Eisai Chemical Co., Ltd. Procédé pour la préparation des dérivés de naphthoquinone et des produits intermédiaires pour leur préparation
WO1999000135A1 (fr) * 1997-06-28 1999-01-07 The Boots Company Plc Compositions de prevention et de traitement de l'osteoporose, comprenant de la vitamine k et de la vitamine d
EP1153548A1 (fr) * 2000-05-12 2001-11-14 Unilever N.V. Produit alimentaire contenant de la vitamine k2

Also Published As

Publication number Publication date
AU2002333378A1 (en) 2003-02-24
WO2003013420A2 (fr) 2003-02-20
EP1414387A2 (fr) 2004-05-06

Similar Documents

Publication Publication Date Title
BE2011C002I2 (en) Aminocyclohexyl ether compounds and uses thereof
CA2129288A1 (fr) Esters phosphonooxymethyliques de derives de taxane
CA2259012A1 (fr) S(-)-tolterodine pour le traitement des troubles urinaires et gastro-intestinaux
AUPQ008299A0 (en) Isoflavone metabolites
AU2291001A (en) Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
WO1999019296A8 (fr) Derives d'acide aminobutanoique
HK1038744A1 (zh) 用於治療炎性疾病的化合物
AU4613999A (en) 2-(purin-9-yl)-tetrahydrofuran-3,4-diol derivatives
CA2260777A1 (fr) Sulfamides de pentafluorobenzene et analogues
CA2259621A1 (fr) Derives d'isocoumarine et utilisation de ces derniers dans des medicaments
WO1999047497A3 (fr) Acides carboxyliques et acylsulfonamides, compositions contenant ces composes et methodes de traitement
GB0117095D0 (en) "Process for the preparation of pure citalopram"
CA2325933A1 (fr) Derives d'acides gras d'acides biliaires et derives d'acide biliaire
CA2336853A1 (fr) Derives d'acide phenoxyacetique et compositions medicinales contenant lesdits derives
CA2244785A1 (fr) Pentafluorobenzenesulfonamides et analogues
AU1266900A (en) Betulinic acid and derivatives thereof useful for the treatment of neuroectodermal tumors
DE69429173D1 (en) Taxolderivate
WO2000021910A3 (fr) Cyclopropanes a disubstitution en position 1 et 2
WO2003013420A3 (fr) Derives d'isoprenyl et leur utilisation pour traiter et prevenir l'osteoporose et la calcification cardio-vasculaire
CA2264005A1 (fr) Derives piperazino a fonction antagoniste de la neurokinine
CA2204747A1 (fr) Derives azoiques d'acide 5-aminosalicylique
EP1900741A8 (fr) Nouveau procédé pour la production d'oxabispidines
WO2002026732A1 (fr) Derive de benzodiazepine
CA2213810A1 (fr) Benzo¬b|thiophenes, intermediaires, procedes, compositions et methodes
GB0218816D0 (en) Antitumoral analogs of lamellarins

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VN YU ZA ZM

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2002794586

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10770991

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 2002794586

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP